中国生物制药:PD-1单抗美获批 涨超 2%

和讯网
25 Apr

【中国生物制药盘中异动,PD-1单抗安尼可获美批准上市】中国生物制药盘中涨超 4%,截至发稿,股价上涨 2.06%,现报 3.97 港元,成交额 2.00 亿港元。4 月 24 日,中国生物制药联合开发的差异化 PD-1 单抗安尼可已获美国食品药品监督管理局批准上市,用于治疗复发或转移性鼻咽癌的一线治疗和用于以铂类为基础的化疗治疗失败的转移性鼻咽癌的两项适应症。据悉,这是中国生物制药首个在美国获批...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10